In a study assessing PD-L1 status in tumor samples, 21% of pancreatic neuroendocrine tumors were positive for PD-L1 expression, and treatment with pembrolizumab resulted in an objective response in 6% of patients with PNET (95% confidence interval [CI] = 0%–30%). Here, CD274 is linked to pancreatic neuroendocrine tumor.